| Original language | English (US) |
|---|---|
| Pages (from-to) | 789-791 |
| Number of pages | 3 |
| Journal | Gastroenterology |
| Volume | 138 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2010 |
ASJC Scopus subject areas
- Hepatology
- Gastroenterology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
The American College of Gastroenterology Irritable Bowel Syndrome Monograph : Translating Systematic Review Data to Clinical Practice. / Moayyedi, Paul; Ford, Alexander C.; Quigley, Eamonn M.M.; Foxx-Orenstein, Amy E.; Chey, William D.; Talley, Nicholas J.; Brandt, Lawrence J.
In: Gastroenterology, Vol. 138, No. 2, 02.2010, p. 789-791.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - The American College of Gastroenterology Irritable Bowel Syndrome Monograph
T2 - Translating Systematic Review Data to Clinical Practice
AU - Moayyedi, Paul
AU - Ford, Alexander C.
AU - Quigley, Eamonn M.M.
AU - Foxx-Orenstein, Amy E.
AU - Chey, William D.
AU - Talley, Nicholas J.
AU - Brandt, Lawrence J.
N1 - Funding Information: Conflicts of interest Paul Moayyedi has received consulting fees from AstraZeneca; lecture fees from Abbot, Procter & Gamble, AstraZeneca, Nycomed, and Johnson & Johnson; and grant support from AstraZeneca and Axcan . Eamonn M.M. Quigley has received consulting fees from Boehringer Ingelheim, Nycomed, Reckitts Benckiser, Salix, AGI Therapeutics, Procter & Gamble, and Ironside; lecture fees from Procter & Gamble, GlaxoSmithKline, Pfizer, Janssen-Cilag, Novartis, Norgine, Danone, and Yakult; and grant support from Procter & Gamble , Pfizer , Alimentary Health , and AGI Therapeutics . He also has equity ownership/stock options in Alimentary Health. Amy E. Foxx–Orenstein, has received consulting fees from Novartis, GlaxoSmithKline, Salix, Easton Associates, MGI Pharma, AstraZeneca, Salix, TAP, Prometheus, and Strategic Consultants; and grant support from Novartis and Salix . William D. Chey has received consulting fess from AGI, Novartis, Procter & Gamble, Salix, Takeda, and Prometheus; and lecture fees from Novartis, Procter & Gamble, Salix, Takeda, and Prometheus. Nicholas J. Talley has received consulting fees from AccreditEd, Addex Pharmaceuticals, SA, the Annenberg Center, Astellas Pharma US, AstraZeneca R&D Lund, Axcan Pharma, Conexus, Dyogen, the F Network, Medscape from WebMD, Metabolic Pharma, MGI Pharma, Microbia, Novartis, Oakstone Publishing, Optum HC, Procter & Gamble, Salix, and SK Life Science. He also holds a patent for Talley BDQ. The remaining authors disclose no conflicts. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2010/2
Y1 - 2010/2
UR - http://www.scopus.com/inward/record.url?scp=75149120507&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=75149120507&partnerID=8YFLogxK
U2 - 10.1053/j.gastro.2009.09.077
DO - 10.1053/j.gastro.2009.09.077
M3 - Letter
C2 - 20026445
AN - SCOPUS:75149120507
VL - 138
SP - 789
EP - 791
JO - Gastroenterology
JF - Gastroenterology
SN - 0016-5085
IS - 2
ER -